Background: Breast MRI is an indispensable modality, along with mammography and US. Its main indications are staging of known cancer, screening for breast cancer in women at increased risk, as part of the routine post-treatment follow-up, being considered more sensitive than conventional imaging investigations in discriminating between postsurgical tissue modifications and tumor relapse and evaluation of response to neoadjuvant chemotherapy. As opposed to mammography and US, MRI is a functional technique. Heywang et al and Kaiser and Zeitler independently introduced this technique in the 1980s. Contrast material–enhanced MRI evaluates the permeability of blood vessels by using an intravenous contrast agent (gadolinium chelate) that shortens the local T1 time, leading to a higher signal on T1-weighted images. The underlying principle is that neoangiogenesis leads to formation of leaky vessels that allow for faster extravasation of contrast agents, thus leading to rapid local enhancement. Despite improvements in the technique of breast MRI, this principle is still the basis of all clinical MRI protocols. However, most MRI protocols nowadays are multiparametric. The standard breast MRI performed in clinical routine relies on both morphologic and dynamic contrast enhancement of lesions. Advanced imaging techniques have been proposed and increasingly used in the last few years. One such technique is diffusion-weighted (DW)-MRI, providing an evaluation of tissue cellularity and integrity of cell membranes. Another technique is the pharmacokinetic analysis of contrast uptake, providing a quantitative assessment of the contrast agent exchange between the vascular and interstitial compartments.